Recent Updates
Recently added Catalysts

Advanced Cutaneous Melanoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.3Buniverse median $1.20B
Allocated capital$634M$1.3B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank188/299crowding rank 198

Advanced Cutaneous Melanoma is uncontested. Immatics (IMTX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with IMA203 in phase 3.

There is no public comparable to price it against. IMTX spreads its $1.3B market cap across 2 indications, so $634M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$634M of allocated capital sits in Advanced Cutaneous Melanoma, ranking it 188th of 299 indications by the money committed to it.

Companies developing drugs for Advanced Cutaneous Melanoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
IMTXImmaticsIMA203Phase 33$1.3BNo2 23 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Advanced Cutaneous Melanoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Advanced Cutaneous Melanoma has one competitor and a median of $1.3B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Castration-Resistant Metastatic Prostate Cancer1 company · $613M · median $1.2BUncontestedMalignant Melanoma1 company · $657M · median $3.9BUncontestedUnresectable Melanoma1 company · $657M · median $3.9BUncontestedRelapsed or Refractory Non-Hodgkin's Lymphoma1 company · $601M · median $601MUncontestedMyelodysplastic Syndromes2 companies · $572M · median $1.5BConcentrated betNon-Muscle Invasive Bladder Cancer (NMIBC)1 company · $723M · median $8.7BUncontestedRefractory Non-Hodgkin's Lymphoma1 company · $723M · median $8.7BUncontestedHPV-Related Carcinoma1 company · $723M · median $8.7BUncontested

Advanced Cutaneous Melanoma pipeline questions

Which biotech companies are developing drugs for Advanced Cutaneous Melanoma?

Immatics (IMTX, IMA203, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Advanced Cutaneous Melanoma.

How advanced is the Advanced Cutaneous Melanoma pipeline?

Of the 1 clinical-stage programme in Advanced Cutaneous Melanoma, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Advanced Cutaneous Melanoma?

No. IMTX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Advanced Cutaneous Melanoma, which is why the indication is classified as uncontested.

When is the next Advanced Cutaneous Melanoma catalyst?

The next dated catalyst in Advanced Cutaneous Melanoma is IMTX on 23 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map